$29.14
-0.31-1.07%
Last update: Nov 12, 10:15 AM
Pfizer Inc
PFENYSE
Pfizer rose 13.5% from $25.87 to $29.36, ahead of the S&P 500's +11.2%. Its worst day was Nov 5 (−4.4%), and its low came Jun 25 at $23.67.
Nov 12, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
FULL-YEAR 2026 REVENUE GUIDANCE(2)Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to approximately $62.0 billion from the range
−3.4% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
EPS of $0.66 beat the $0.56 estimate on $17.6B revenue (est. $16.9B); FY revenue guidance of $59.5B–$62.5B against the $60.9B consensus.
−3.3% · S&P 500 −0.8%
EPS of $0.75 beat the $0.72 estimate on $14.5B revenue (est. $13.8B); FY revenue guidance of $59.5B–$62.5B against the $61.3B consensus.
+0.6% · S&P 500 +0.8%
Pfizer closed at its lowest level of the year, 8.5% below where the year started.
−1.5% · S&P 500 +0.1%
EPS of $0.77 beat the $0.68 estimate on $15.0B revenue (est. $14.4B); FY revenue guidance of $60.5B–$62.5B against the $61.7B consensus.
+1.5% · S&P 500 +1.8%
Pfizer shares rose 3.6%, while the S&P 500 rose 0.2%.
+3.6% · S&P 500 +0.2%
EPS of $0.87 beat the $0.73 estimate on $16.6B revenue (est. $15.9B); FY revenue guidance of $62.0B–$64.0B against the $62.3B consensus.
−2.2% · S&P 500 +0.3%
Where it ended: a close of $29.36 on Nov 10, 2026. Up next: Q4 2026 earnings on Feb 2, 2027 (EPS est. $0.69, revenue est. $17.2B).
As of the Nov 10, 2026 close
Replay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PFE and SPY from Benzinga historical bars. Not investment advice.
